| Title |
Antitumor activity of pluripotent cell-engineered vaccines and their potential to treat lung cancer in relation to different levels of irradiation
|
|---|---|
| Published in |
OncoTargets and therapy, March 2016
|
| DOI | 10.2147/ott.s97587 |
| Pubmed ID | |
| Authors |
Yan-na Zhang, Xiao-gang Duan, Wen-hui Zhang, Ai-ling Wu, Huan-Huan Yang, Dong-ming Wu, Yu-Quan Wei, Xian-cheng Chen |
| Abstract |
Cancer stem cells (CSCs) are critical for tumor initiation/maintenance and recurrence or metastasis, so they may serve as a potential therapeutic target. However, CSC-established multitherapy resistance and immune tolerance render tumors resistant to current tumor-targeted strategies. To address this, renewable multiepitope-integrated spheroids based on placenta-derived mesenchymal stem cells (pMSCs) were X-ray-modified, at four different irradiation levels, including 80, 160, 240, and 320 Gy, as pluripotent biologics, to inoculate hosts bearing Lewis lung carcinoma (LL2) and compared with X-ray-modified common LL2 cells as control. We show that the vaccines at the 160/240 Gy irradiation levels could rapidly trigger tumor cells into the apoptosis loop and evidently prolong the tumor-bearing host's survival cycle, in contrast to vaccines irradiated at other levels (P<0.05), with tumor-sustaining stromal cell-derived factor-1/CXCR4 pathway being selectively blockaded. Meanwhile, almost no or minimal toxicity was detected in the vaccinated hosts. Importantly, 160/240 Gy-irradiated vaccines could provoke significantly higher killing of CSCs and non-CSCs, which may provide an access to developing a novel biotherapy against lung carcinoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 2 | 18% |
| Student > Bachelor | 1 | 9% |
| Student > Master | 1 | 9% |
| Researcher | 1 | 9% |
| Professor > Associate Professor | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 5 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 18% |
| Biochemistry, Genetics and Molecular Biology | 1 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
| Social Sciences | 1 | 9% |
| Immunology and Microbiology | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 5 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2023.
All research outputs
#8,535,684
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#547
of 3,016 outputs
Outputs of similar age
#112,703
of 312,601 outputs
Outputs of similar age from OncoTargets and therapy
#19
of 108 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,601 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.